SV

Street Verdict

Analyst Scorecard

A record of what HSBC Analysis said publicly, with the source. Not advice.

Pending — not yet graded
“Initiated coverage on Manipal Health with a 'Buy' rating and a target price of ₹1,000, indicating a 25.32% upside from its last price. The brokerage expects Manipal Health to sharpen its focus on profitability after doubling bed capacity since FY23, with profit after tax potentially tripling between FY26 and FY29, and net debt improving to 0.7 times estimated FY27 EBITDA.”

HSBC Analysis’s track record (trackable calls only): 34 graded calls · 95% CI 31–63%

Manipal HealthBullishCalled 28 Aug 2026
Verdict:PENDING

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹1,000, as stated.

Window: 12 months, the default when no time frame is stated.

Window still open: no verdict until a close reaches a level or the window ends.

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Tracking Manipal Health since this call

1-year tracking window
Read the original articleSee HSBC Analysis’s full track record